Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Apr 10, 2016 · 55s
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Description
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Information
Author cancerGRACE
Organization cancerGRACE
Website -
Tags

Looks like you don't have any active episode

Browse Spreaker Catalogue to discover great new content

Current

Podcast Cover

Looks like you don't have any episodes in your queue

Browse Spreaker Catalogue to discover great new content

Next Up

Episode Cover Episode Cover

It's so quiet here...

Time to discover new episodes!

Discover
Your Library
Search